177 related articles for article (PubMed ID: 19441846)
1. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
Kinzel O; Llauger-Bufi L; Pescatore G; Rowley M; Schultz-Fademrecht C; Monteagudo E; Fonsi M; Gonzalez Paz O; Fiore F; Steinkühler C; Jones P
J Med Chem; 2009 Jun; 52(11):3453-6. PubMed ID: 19441846
[TBL] [Abstract][Full Text] [Related]
2. The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.
Hamblett CL; Methot JL; Mampreian DM; Sloman DL; Stanton MG; Kral AM; Fleming JC; Cruz JC; Chenard M; Ozerova N; Hitz AM; Wang H; Deshmukh SV; Nazef N; Harsch A; Hughes B; Dahlberg WK; Szewczak AA; Middleton RE; Mosley RT; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2007 Oct; 17(19):5300-9. PubMed ID: 17761416
[TBL] [Abstract][Full Text] [Related]
3. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
Jones P; Altamura S; De Francesco R; Paz OG; Kinzel O; Mesiti G; Monteagudo E; Pescatore G; Rowley M; Verdirame M; Steinkühler C
J Med Chem; 2008 Apr; 51(8):2350-3. PubMed ID: 18370373
[TBL] [Abstract][Full Text] [Related]
4. Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities.
Maeda T; Nagaoka Y; Kuwajima H; Seno C; Maruyama S; Kurotaki M; Uesato S
Bioorg Med Chem; 2004 Aug; 12(16):4351-60. PubMed ID: 15265487
[TBL] [Abstract][Full Text] [Related]
5. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.
Andrews DM; Stokes ES; Carr GR; Matusiak ZS; Roberts CA; Waring MJ; Brady MC; Chresta CM; East SJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2580-4. PubMed ID: 18378449
[TBL] [Abstract][Full Text] [Related]
6. Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2).
Heidebrecht RW; Chenard M; Close J; Dahlberg WK; Fleming J; Grimm JB; Hamill JE; Harsch A; Haines BB; Hughes B; Kral AM; Middleton RE; Mushti C; Ozerova N; Szewczak AA; Wang H; Wilson K; Witter DJ; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2009 Apr; 19(7):2053-8. PubMed ID: 19268585
[TBL] [Abstract][Full Text] [Related]
7. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
9. Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
Pescatore G; Kinzel O; Attenni B; Cecchetti O; Fiore F; Fonsi M; Rowley M; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2008 Oct; 18(20):5528-32. PubMed ID: 18809328
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
Moffat D; Patel S; Day F; Belfield A; Donald A; Rowlands M; Wibawa J; Brotherton D; Stimson L; Clark V; Owen J; Bawden L; Box G; Bone E; Mortenson P; Hardcastle A; van Meurs S; Eccles S; Raynaud F; Aherne W
J Med Chem; 2010 Dec; 53(24):8663-78. PubMed ID: 21080647
[TBL] [Abstract][Full Text] [Related]
11. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB
Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
Thaler F; Colombo A; Mai A; Amici R; Bigogno C; Boggio R; Cappa A; Carrara S; Cataudella T; Fusar F; Gianti E; di Ventimiglia SJ; Moroni M; Munari D; Pain G; Regalia N; Sartori L; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C; Varasi M
J Med Chem; 2010 Jan; 53(2):822-39. PubMed ID: 20017493
[TBL] [Abstract][Full Text] [Related]
13. N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
Wang H; Yu N; Song H; Chen D; Zou Y; Deng W; Lye PL; Chang J; Ng M; Sun ET; Sangthongpitag K; Wang X; Wu X; Khng HH; Fang L; Goh SK; Ong WC; Bonday Z; Stünkel W; Poulsen A; Entzeroth M
Bioorg Med Chem Lett; 2009 Mar; 19(5):1403-8. PubMed ID: 19181524
[TBL] [Abstract][Full Text] [Related]
14. Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
Witter DJ; Harrington P; Wilson KJ; Chenard M; Fleming JC; Haines B; Kral AM; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2008 Jan; 18(2):726-31. PubMed ID: 18060775
[TBL] [Abstract][Full Text] [Related]
15. Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.
Payne JE; Bonnefous C; Hassig CA; Symons KT; Guo X; Nguyen PM; Annable T; Wash PL; Hoffman TZ; Rao TS; Shiau AK; Malecha JW; Noble SA; Hager JH; Smith ND
Bioorg Med Chem Lett; 2008 Dec; 18(23):6093-6. PubMed ID: 18954983
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
[TBL] [Abstract][Full Text] [Related]
17. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
Wang H; Yu N; Chen D; Lee KC; Lye PL; Chang JW; Deng W; Ng MC; Lu T; Khoo ML; Poulsen A; Sangthongpitag K; Wu X; Hu C; Goh KC; Wang X; Fang L; Goh KL; Khng HH; Goh SK; Yeo P; Liu X; Bonday Z; Wood JM; Dymock BW; Kantharaj E; Sun ET
J Med Chem; 2011 Jul; 54(13):4694-720. PubMed ID: 21634430
[TBL] [Abstract][Full Text] [Related]
18. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
[TBL] [Abstract][Full Text] [Related]
19. Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor.
Suzuki T; Hisakawa S; Itoh Y; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
Bioorg Med Chem Lett; 2007 Mar; 17(6):1558-61. PubMed ID: 17257837
[TBL] [Abstract][Full Text] [Related]
20. Alpha-mercaptoketone based histone deacetylase inhibitors.
Wash PL; Hoffman TZ; Wiley BM; Bonnefous C; Smith ND; Sertic MS; Lawrence CM; Symons KT; Nguyen PM; Lustig KD; Guo X; Annable T; Noble SA; Hager JH; Hassig CA; Malecha JW
Bioorg Med Chem Lett; 2008 Dec; 18(24):6482-5. PubMed ID: 18954984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
